MannKind Q2 revenue $76.5M (+6% YoY); Afrezza sBLA for pediatric population submitted

MANNKIND CORP

2025-Q2 EPS reported $0.04 revenue$154,881,000

Total revenues $76.5M, up 6% YoY; net income $0.7M versus net loss $2.0M in Q2 2024.
Afrezza sales $18.3M (+13% YoY); royalties from Tyvaso DPI $31.2M (+22%).
Non-GAAP net income $13.9M ($0.05/share) vs $14.3M ($0.05) in Q2 2024.
Submitted sBLA for Afrezza in pediatric patients (ages 4-17); FDA decision expected early Q4 2025.
ICoN-1 trial of MNKD-101 enrollment ahead of schedule; interim target of 100 patients expected early Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.